DWT
VTGN icon

Dorsey & Whitney Trust’s VistaGen Therapeutics VTGN Stock Holding History

Dorsey & Whitney Trust’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,000
Closed -$132K – 568
2022
Q2 		$132K Buy
5,000
+2,500
+100% +$88.3K 0.01% 520
2022
Q1 		$93K Buy
2,500
+1,833
+275% +$79.9K 0.01% 561
2021
Q4 		$39K Hold
667
– – ﹤0.01% 561
2021
Q3 		$55K Buy
+667
New +$58K 0.01% 542

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dorsey & Whitney Trust's VTGN Position: Q3 2022 in Review

Dorsey & Whitney Trust sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 5,000 shares — an estimated $132K sold.

Dorsey & Whitney Trust first reported a position in VTGN in Q3 2021 and held it in 4 quarters. The position peaked at $132K in Q2 2022. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

  • Dorsey & Whitney Trust reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Dorsey & Whitney Trust sold 5,000 VistaGen Therapeutics shares in Q3 2022, an estimated $132K.
  • Dorsey & Whitney Trust first reported a position in VistaGen Therapeutics in Q3 2021 and held it in 4 quarters.
  • Dorsey & Whitney Trust's VistaGen Therapeutics position peaked at $132K in Q2 2022.
  • 92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on Dorsey & Whitney Trust's 13F filing for Q3 2022, filed 14 Nov 2022.